AngioDynamics Inc. (NASDAQ:ANGO)’s share price traded down 6.4% during mid-day trading on Tuesday . The stock traded as low as $15.21 and last traded at $15.46, with a volume of 3,077,677 shares changing hands. The stock had previously closed at $16.52.

Several equities analysts have issued reports on the company. Piper Jaffray Cos. assumed coverage on AngioDynamics in a research report on Friday, April 8th. They set a “neutral” rating and a $12.00 target price on the stock. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Wednesday, April 20th. Finally, KeyCorp lowered their price target on AngioDynamics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, April 8th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. AngioDynamics currently has a consensus rating of “Hold” and an average price target of $14.10.

The stock’s 50 day moving average price is $15.02 and its 200-day moving average price is $12.48. The company’s market cap is $558.71 million.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, July 13th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $88.64 million. During the same quarter in the prior year, the business earned $0.14 EPS. AngioDynamics’s revenue was up 2.8% compared to the same quarter last year. On average, equities research analysts forecast that AngioDynamics Inc. will post $0.63 earnings per share for the current year.

In related news, VP Charles R. Greiner sold 3,508 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $12.31, for a total transaction of $43,183.48. Following the transaction, the vice president now owns 20,910 shares in the company, valued at $257,402.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

A number of hedge funds and institutional investors have bought and sold shares of ANGO. Nationwide Fund Advisors raised its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock valued at $1,073,000 after buying an additional 63,332 shares during the period. Morgan Stanley raised its position in AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period. Whitebox Advisors LLC acquired a new position in AngioDynamics during the fourth quarter valued at about $1,384,000. Royce & Associates LLC raised its position in AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period. Finally, Lapides Asset Management LLC raised its position in AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock valued at $8,504,000 after buying an additional 8,400 shares during the period.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.